Armin Hekele
About Armin Hekele
Armin Hekele is the Head of Virology and Molecular Biology at BridgeBio, with extensive experience in the biotechnology and pharmaceutical sectors, including previous roles at Novartis Vaccines and Precision BioSciences.
Current Role at BridgeBio
Armin Hekele serves as the Head of Virology and Molecular Biology at BridgeBio since 2019. In this role, he oversees research initiatives focused on viral diseases and molecular biology, contributing to the company's mission of developing innovative therapies. His leadership in this position reflects his extensive background in virology and molecular research.
Previous Experience at Novartis Vaccines
Armin Hekele has held multiple positions at Novartis Vaccines between 2008 and 2015. He began as an Investigator and progressed to Investigator II, Senior Scientist, and Head of Laboratory. His tenure at Novartis Vaccines spanned various roles, allowing him to develop expertise in vaccine research and development.
Experience at Precision BioSciences, Inc.
Hekele worked at Precision BioSciences, Inc. from 2015 to 2019, where he held the positions of Senior Scientist and later Director of Molecular Biology. His work focused on advancing molecular biology techniques and applications, contributing to the company's research objectives in gene editing and therapeutic development.
Educational Background in Biochemistry and Immunology
Armin Hekele earned his M.Sc. in Biochemistry from the University of Wuerzburg, Germany, from 1985 to 1990. He furthered his education by obtaining a Ph.D. in Immunology from the University of Karlsruhe, Germany, from 1991 to 1995. This academic foundation has significantly influenced his research career in virology and molecular biology.
Postdoctoral Research Experience
Hekele has a notable postdoctoral research background, including positions at Roche Diagnostics and the German Cancer Research Center (dkfz). He worked as a Postdoctoral Researcher at Roche Diagnostics from 1997 to 1999 and as a Postdoctoral Fellow at dkfz in 1996. These experiences contributed to his expertise in cancer biology and molecular research.